{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P55036",
      "entity_text" : "AF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5462224",
      "entity_text" : "mg",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Moreover, RAFFAELLO trial 29 demonstrated that ranolazine in doses of 500 and 750 mg reduced AF recurrences compared to placebo (borderline significance).",
  "reading_complete" : "2020-08-03T09:37:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T09:36:31Z",
  "trigger" : "reduced",
  "evidence" : [ "mg reduced AF" ],
  "pmc_id" : "5494397",
  "score" : 0
}